ADC
Ryvu’s ADCs (antibody-drug conjugates) are based on a new generation of payloads with synthetic lethal and immunomodulatory activity.
An ADC is a modern form of targeted therapy in which a small-molecule drug is combined with a monoclonal antibody. The antibody recognizes and binds to a specific antigen on the surface of cancer cells, allowing the payload to be delivered directly to the tumor, minimizing damage to healthy tissues and limiting side effects.
Key highlights
An ADC consists of three main components:
- A monoclonal antibody that precisely recognizes cancer cells
- Cytotoxic payload/active substance (payload) – a chemical molecule that destroys the tumor
- Linker – a stable linker that controls the release of the drug at the appropriate site
The advantages of ADCs represent a promising for treating various types of cancer, especially those that are difficult to treat with standard therapies.
Ryvu Technology
program
indication
discovery
PRECLINICAL
PHASE I
PHASE II
partner
program
ADCs – Novel Payloads
indication
Oncology
discovery
PRECLINICAL
PHASE I
PHASE II
Contact
FOR MEDICAL PROFFESIONALS & INVESTIGATORS
If you are a medical professional, an investigator for a RYVU trial, or would like information about becoming an investigator, please contact us at [email protected] or use contact form.
